RLT Connect. Changing lives, one patient at a time
The RLT-Connect platform is an online platform designed to facilitate collaboration between healthcare professionals seeking radioligan therapy for their patients who cannot afford it, and Radioisotope suppliers willing to donate doses to make this life-savings treatment accessible to those in need.
How can I take part in this initiative?
Hear from the community
Changing lives, one patient at a time
Access to radioligand therapies is deeply unequal around the world:
- Technology only available to a small number of cancer patients
- Access is dependent on where the patient lives
- In most low- and middle-income new radiopharmaceuticals are paid out of pocket
Connections are low and sometimes nonexistent.
It’s all about connections.
Our generous supporters
Frequently Asked Questions
A collaborative platform implemented by the Oncidium foundation to enable radioligand therapy treatments for patients who cannot afford it in countries that already have the infrastructure to deliver such therapies.
The RLT-Connect platform connects healthcare practitioners and Radioisotope companies, that donate Radioisotope doses to be able to provide radioligand therapy for those who cannot otherwise afford it.
The RLT-Connect platform is an Oncidium foundation initiative. Oncidium is acting as a facilitator to connect and establish an effective and operational ecosystem between HCPs, Radioisotope companies and local radiopharmacies to provide donated doses for patients that cannot afford the treatment cost. Oncidium’s role is limited to:
• Facilitating the connections between HCPs and Radioisotope suppliers;
• Evaluating the clinical sites requests according to pre-defined eligibility criteria for centers and the Ethics charter;
• Setting up and hosting the online RLT-Connect platform
Clinical Sites
• Selection of patients and creation of paperwork for treatment access: early access, compassionate use, expanded access, etc.
• Submission of cases on online platform
• Contact with local Radiopharmacy for the logistics, Labeling and QC.
• Feedback on treatment outcomes
Local Radiopharmacies
• Importation process, customs clearance, inland transportation.
• Labeling and QC
• Delivery at clinical site
Isotope suppliers
• Dose donations
• Definition of number of doses to be donated each year
• Healthcare professionals working in centers that already use 177Lu and that have experience in treating patients with 177Lu radiopharmaceuticals. Thus, patients cannot register themselves to seek a dose.
• Radioisotopes suppliers that wish to donate radioisotopes (including dose donation, shipment, importation taxes).
The RLT-Connect is currently donating 177LuCl (lutetium-177 (177Lu) chloride).
Patients who cannot afford the therapy, mainly from low- and medium-income countries, where there is no reimbursement. Dose distribution is limited for each country and will be allocated evenly across the world.
Healthcare professionals, in countries where the necessary infrastructure is already implemented to deliver the doses to the patients. Moreover, patients cannot register themselves to seek a dose, the request should come from the hospital that can deliver the treatment.
What’s more, once the donation is approved, doses are donated by the Radioisotopes Companies and directly to the centers and will not transit through the Oncidium foundation.
Once a case is accepted and validated for donation to a patient, the foundation commits to providing the necessary doses, including a full treatment cycle personalized to the patient’s needs. Additionally, patients who have already received doses and require additional ones may also benefit from the donation in case they meet the eligibility criteria established for the program. On the other hand, if a patient does not respond to the treatment, the doses will be reallocated to another patient in need, ensuring efficient use of resources.
An Ad Hoc committee set up by the Oncidium foundation composed of field specialist.
The labelling will be carried out by the Radiopharmacy center that already works with the hospitals. It must be indicated in the registration form.
The importation and logistics of the 177LuCl dose will follow the same process as already done by your center for commercial doses. The Oncidium foundation does not intermediate these processes.
1- Register your center here https://rlt-connect.oncidiumfoundation.org/registration/clinical/;
2- Receive the confirmation of the registration request by e-mail;
3- If your center registration is approved, you will receive by e-mail a contract and the RLT-Connect ethical charter to be signed by the physician and the hospital director;
4- An additional document will also be attached, to the local Radiopharmacy your hospital is working with for signature;
5- Once the contracts are signed, you will be able to request a dose;
6- To request a dose, log into the platform: https://rlt-connect.oncidiumfoundation.org/;
7- Click on “Create a request”;
8- Answer the qualifying criteria form and submit it;
9- After careful consideration of the request, you will receive a response within 15 working days, indicating either a positive or negative return.